Browse medicines, page 20 of 43

Use listed on the medicine record

Fenoprofen calcium is indicated for: • Relief of mild to moderate pain in adults • Relief of the signs and symptoms of rheumatoid arthritis • Relief of the signs and symptoms of osteoarthritis Fenoprofen calcium is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. ( 1 ) • Relief of the signs and symptoms of rheumatoid arthritis. ( 1 ) • Relief of the signs and symptoms of osteoarthritis. ( 1 )

Use listed on the medicine record

Iron deficiency anemia

Use listed on the medicine record

Serum phosphorus levels

Use listed on the medicine record

SUGGESTED USE Adults: One (1) tablet daily, preferably after meals or as directed by the doctor. Children: As directed by the doctor.

Use listed on the medicine record

Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

Use listed on the medicine record

Acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus

Use listed on the medicine record

TASCENSO ODT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Use listed on the medicine record

Use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary

Use listed on the medicine record

Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. Fluorodopa F 18 Injection is a radioactive diagnostic agent indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).

Use listed on the medicine record

Use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy

Use listed on the medicine record

INDICATIONS & USAGE Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.

Use listed on the medicine record

Fluphenazine Decanoate Injection, USP is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection, USP has not been shown effective in the management of behavioral complications in patients with mental retardation.

Use listed on the medicine record

The inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Use listed on the medicine record

Positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress

Use listed on the medicine record

Positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density

Use listed on the medicine record

Obsessive compulsive disorder

Use listed on the medicine record

CMV retinitis

Use listed on the medicine record

The risk of mortality

Use listed on the medicine record

CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

Use listed on the medicine record

AnubisMed 50+ Protection Fluid Indications and Usage

Use listed on the medicine record

Cluster headache

Use listed on the medicine record

LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Intravenous use

Use listed on the medicine record

AMBELVIST is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) AMBELVIST is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine,…

Use listed on the medicine record

Magnetic resonance imaging (MRI) to visualize

Use listed on the medicine record

Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Use listed on the medicine record

Cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) [see

Use listed on the medicine record

、 Clean and dry the face 2、 Apply an appropriateamount of face cream evenly on the face 3、Gently massage until absorbed

Use listed on the medicine record

Indication 1.Tear open the package, take out the patch, peel off the white anti-adhesive layer, and stick the patchbehind the ear or the navel (please dry the sweat from the ear and the navel). 2.Use it 10 minutes before boarding a car, airplane or boat.*lf the symptoms are severe, you can use 2 patches on both ears or on one ear and navel

Use listed on the medicine record

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic

Use listed on the medicine record

Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies (14 ) ] . Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [see Clinical Studies (14) ] .

Use listed on the medicine record

Advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy

Use listed on the medicine record

temporarily relieves burning and irritation of the eye. prevent further irritation of the eye.

Use listed on the medicine record

Major depressive disorder

Use listed on the medicine record

push the puff gently into the cushion and apply it from larger areas to smaller areas spread it evenly by lishtly patting onto the skin

Use listed on the medicine record

Adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test

Use listed on the medicine record

The inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Use listed on the medicine record

▪ Helps relieve symptoms of fungal and inflammatory skin conditions, including: – Folliculitis – Dandruff – Seborrheic dermatitis – Tinea versicolor – Jock itch ▪ Reduces itching, flaking, redness, and irritation

Use listed on the medicine record

Spray directly onto closed eyelids or applyusing a sterile cotton pad Gently wipe acrossthe eyelid and lash line Use 1-2 times daily oras recommended by your eye care professional If you wear contact lenses, please removethem before use For external eyelid use only

Use listed on the medicine record

The following serious infections caused by designated susceptible bacteria

Use listed on the medicine record

Symptoms of depression

Use listed on the medicine record

ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously.